Angiogenin and angiopoietin-2 secretion (ANG/ANGPT2 secretion)

Angiogenin and angiopoietin-2 secretion refers to the extracellular release of two distinct proteins that play pivotal roles in the regulation of angiogenesis and vascular maintenance. Angiogenin (ANG) is a 14.4 kDa member of the ribonuclease A superfamily that promotes endothelial cell proliferation and basement membrane degradation by stimulating ribosomal RNA transcription (UniProt P03950). Angiopoietin-2 (ANGPT2) is a context-dependent antagonist of the Tie2 receptor that facilitates vascular destabilization, allowing for vessel sprouting in the presence of vascular endothelial growth factor (VEGF) (UniProt O15123). The simultaneous secretion of these factors is frequently observed in pathological states such as solid tumor progression and neovascular ocular diseases, where they drive abnormal blood vessel growth and increase vascular permeability (PubMed 21441931, PubMed 25100623). While ANGPT2 is a validated therapeutic target addressed by drugs like Faricimab, which neutralizes both ANGPT2 and VEGF-A, Angiogenin is primarily a target of experimental research in oncology and neuroprotection (FDA Label: Vabysmo). This entry is considered incorrect as a single target because it describes a physiological process involving two separate molecular entities rather than a single druggable receptor or enzyme.

Other names

ANG and ANGPT2 releaseAngiogenic factor secretionSecreted angiogeninSecreted angiopoietin-2

Inhibition of ligand-receptor binding (e.g., ANGPT2 to Tie2) or neutralization of the secreted factors to prevent downstream angiogenic signaling and vascular destabilization.